[1] |
XU Yuanyuan, GUO Linghong, WU Shuwei, ZHANG Ting, ZHANG Lu, JIANG Xian.
Causal associations between three atopic diseases and alopecia areata: a two-sample Mendelian randomization study
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(4): 239-244.
|
[2] |
CHEN Xi, LIU Guoyan.
Update of PRP in alopecia areata
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(4): 301-306.
|
[3] |
HAN Jinghong, LIU Hong.
Two children with refractory atopic dermatitis successfully treated with Janus kinase inhibitors
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 190-192.
|
[4] |
CHANG Jiayu, QI Miao, WANG Yimin, LI Yongxi, SHI Tongxin.
Bullous pemphigoid occurred in a patient with severe plaque psoriasis treated with secukinumab: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 199-201.
|
[5] |
XU Yang, ZHAN Weisheng, ZHAO Juhua.
Efficacy and safety of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis: a meta-analysis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(2): 89-94.
|
[6] |
CUI Yinling, ZHENG Chunzhi, YU Yongmei, LIU Hong.
Palmoplantar psoriasis resistant to secukinumab successfully treated with tofacitinib: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(2): 134-136.
|
[7] |
DENG Yazhi, KANG Xiaojing, DING Yuan.
Update of correlation between psoriasis and malignant tumors
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(2): 139-144.
|
[8] |
ZHANG Yuting, ZHAO Huixia, MENG Xin, ZHAO Jiale, HE Xiaoyuan.
Changes of skin and intestinal microflora in psoriasis mice based on 16S rRNA sequencing
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 15-20.
|
[9] |
DU Baiyinzi, WANG Huiping, LUO Suju.
Efficacy and safety comparation of adalimumab and secukinumab in the treatment of nail psoriasis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 26-30.
|
[10] |
LI Xiaoxian, LI Jianke, WANG Xiuhuan, LIU Xinzhou, LIU Guoyan.
Diffuse alopecia areata after COVID-19 vaccine treated with baricitinib: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 31-35.
|
[11] |
ZHOU Xiaonan, CAO Chunyan, SHI Yaping, QI Maoxuan, ZHANG Qianying, ZONG Yan.
Latent profile analysis of family management characteristics in children with atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 39-44.
|
[12] |
LEI Mingjun, DU Yinghua, TIAN Zan, BAI Fan.
Secukinumab in the treatment of plaque psoriasis complicated with uveitis: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 45-47.
|
[13] |
MAN Chunhua, WANG Xianzhen, WANG Xiangtong, LI Yangyang, WANG Qing.
Effect of abrocitinib in a patient with secukinumab-induced eczematous eruption: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 56-58.
|
[14] |
WEI Mingjing, CHEN Wenqi.
Update of TRPV3 in the occurrence and treatment of skin diseases
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 66-70.
|
[15] |
ZHENG Chunzhi, ZHANG Weilin, GUO Xiao, YANG Baoqi, YANG Qing, LIU Hong.
Efficacy and safety of ixekizumab and adalimumab in the treatment of moderate to severe plaque psoriasis
[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(9): 633-638.
|